Nomura: ESMO China drug advances: Innovent, Akeso and Kelun have shown survival benefits, while Hengrui’s focus is disease control
Nomura reviewed the ESMO 2026 clinical results: Innovent’s IBI343, Akeso’s ivonescimab and Kelun-Biotech’s sac-TMT improved overall survival in specific indications; the benefits in some other trials were mainly reflected in delayed disease progression, and the maturity of overall survival data is key to understanding the results.